FDA approves Zepbound® (tirzepatide) as the first and only …
INDIANAPOLIS, Dec. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound ® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. 1 Zepbound may help adults with moderate-to-severe ...
Eli Lilly to sell Zepbound directly to consumers without ... - ABC News
Aug 27, 2024 · Eli Lilly, the maker of Zepbound, announced Tuesday it will begin selling the weight loss drug directly to consumers through the company's direct pharmacy, LillyDirect.
Lilly releases Zepbound® (tirzepatide) single-dose vials, …
INDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Zepbound ® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand.
FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight ...
Nov 8, 2023 · Zepbound is the first and only approved treatment activating two incretin hormone receptors, GIP and GLP-1, to tackle an underlying cause of excess weight.
Lilly launches lower-price weight loss drug without injector pen - CNN
Aug 27, 2024 · Starter doses of the weight-loss drug Zepbound are now available in single-dose vials, drug manufacturer Eli Lilly announced Tuesday, a move the company says will “significantly” expand supply...
FDA Approves First Medication for Obstructive Sleep Apnea
Zepbound also contains warnings for inflammation of the pancreas (pancreatitis), gallbladder problems, hypoglycemia (blood sugar that is too low), acute kidney injury, diabetic retinopathy (damage ...
FDA approves weight loss drug Zepbound for sleep apnea - NBC News
Dec 20, 2024 · The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in adults with obesity, the drugmaker Eli Lilly said Friday. The decision...
FDA approves Eli Lilly’s Zepbound, a weight loss drug ... - NBC News
Nov 8, 2023 · The Food and Drug Administration on Wednesday approved Zepbound, a new weight loss drug from drugmaker Eli Lilly that was shown in clinical trials to help people lose up to 52 pounds in 16...
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea
Dec 20, 2024 · The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.
Zepbound tops Wegovy for weight loss in Eli Lilly study
Dec 4, 2024 · Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk.